SCN-101 (COVID-19 hIVIG)
Severe COVID-19
Key Facts
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a clinical-stage biotech company with a dual mission: advancing its own pipeline of antibody therapies for infectious and autoimmune diseases while operating a contract development and manufacturing organization (CDMO) to fund its research. Its key strategic asset is a state-of-the-art cGMP biologics manufacturing facility in Jerusalem, providing end-to-end control from discovery to production. The company's public listings on NASDAQ (SCNI) and the Tel Aviv Stock Exchange support its goal of leveraging service revenue to de-risk and accelerate its proprietary drug development programs.
View full company profileAbout Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a clinical-stage biotech company with a dual mission: advancing its own pipeline of antibody therapies for infectious and autoimmune diseases while operating a contract development and manufacturing organization (CDMO) to fund its research. Its key strategic asset is a state-of-the-art cGMP biologics manufacturing facility in Jerusalem, providing end-to-end control from discovery to production. The company's public listings on NASDAQ (SCNI) and the Tel Aviv Stock Exchange support its goal of leveraging service revenue to de-risk and accelerate its proprietary drug development programs.
View full company profileTherapeutic Areas
Other Severe COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| Severe Covid | Genclis | Discovery |
| Exvastat Program | Numedicus | Phase 2 |
| CSL324 | CSL | Phase 3 |